Please Wait.....
Report
Neuropathic Pain Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 110 Pages I Mordor Intelligence
The Neuropathic Pain market studied is anticipated to grow at a CAGR of 5.5% during the forecast period (2022-2027).
COVID-19 has led to unprecedented effects on the healthcare sector. Public health measures to combat the spread of COVID-19 such as social distancing and shelter-in-place orders have impacted every stage of therapeutic development, from basic science to manufacturing and distribution of both approved and experimental neurological therapeutics. Additionally, COVID-19 has significantly impacted neurological health as well. For instance, in March 2022, researchers at Washington University School of Medicine found that many people who tested positive for the coronavirus in the early months of the pandemic also experienced peripheral neuropathy pain, tingling, and numbness in the hands and feet during and following their bouts with COVID-19. Such an increase in neuropathy pain due to COVID-19 has created the need for treatment amid the outbreak, thereby boosting the market's growth over the pandemic phase.
Specific factors driving the market growth include the rising prevalence of diabetic neuropathy and other targeted diseases and increasing healthcare expenditure and research funding. As per the International Diabetes Federation (IDF) Diabetes Atlas 10th edition, 537 million adults aged 20 to 79 will be living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Such a high burden of diseases that can lead to neuropathic pain creates the need for therapeutics for the treatment and thus propels the growth of the market.
Additionally, the approval of the drugs by the regulatory authorities of the different regions is also contributing to the growth of the market. For instance, in July 2020, Grunenthal and its United States subsidiary, Averitas Pharma, Inc., received United States Food and Drug Administration (FDA) approval for QUTENZA (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. It is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription-strength capsaicin directly into the skin. Such approvals of the different routes of administration of drugs are expected to propel the growth of the market.
Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, side effects of treatments and the availability of counterfeit drugs may hinder the growth of the market.
Neuropathic Pain Market Trends
Diabetic Neuropathy Segment is Expected to Hold Significant Share Over the Forecast Period.
The diabetes neuropathy segment of the market is expected to show significant growth over the forecast period. The major factors driving the growth of the segment are the increasing burden of the targeted diseases coupled with the launch of the products for their treatment.
Sedentary and unhealthy lifestyles are major factors that contribute to the large prevalence of diabetes around the world. For instance, according to the article titled "Epidemiology and classification of diabetic neuropathy" updated in January 2021, diabetic polyneuropathy is the most common neuropathy in developed countries. It also reported that approximately 50% of patients with diabetes will eventually develop neuropathy. Such studies demonstrating the chances of neuropathy in diabetic patients suggest that there is a growing burden of this disease. Hence, this market segment is expected to show growth over the forecast period.
Additionally, the increasing research studies and clinical trials can lead to the development of new products and thus may drive the growth of the segment in the future. For instance, in May 2021, Pure Green Pharmaceuticals Inc. reported that in a Phase II trial, a cannabidiol (CBD) sublingual tablet reduced pain scores in patients with diabetic peripheral neuropathy by approximately 50%. Such positive results from the studies may propel the growth of the segment over the forecast period.
Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.
North America Dominates the Global Neuropathic Pain Market Over the Forecast Period
Due to university and hospital priorities to deal with the COVID-19 (SARS-CoV-2) outbreak as quickly as possible, residency programs have been disrupted in the North American region. The majority of research and clinical trials have been temporarily halted or postponed. Moreover, activities related to neurology, such as medical training and research, were disrupted due to the pandemic. The COVID-19 pandemic had a considerable impact on drug development for neurological disorders in 2020, causing clinical studies to be interrupted by shelter-in-place orders and making it difficult to safely collect biofluid samples.
In the North American region, the United States has accounted for the largest market share. The presence of significant market players and huge pharmaceutical and biopharmaceutical industries, coupled with the rising investments in the country for the adoption of advanced technologies, is expected to boost the regional growth of the market over the forecast period.
Various initiatives by market players are also driving the market's growth in the region. The market players are conducting research studies to develop effective treatment drugs for neuropathic pain, which is also contributing to the growth of the market. For instance, in September 2021, Biogen Inc. reported positive topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074), a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy (SFN). Such positive results in different phases of the clinical studies could lead to the development of the drug in the future and hence drive the growth of the market.
Thus, owing to the abovementioned factors, the market in North America is expected to show growth over the forecast period.
Neuropathic Pain Market Competitor Analysis
The global neuropathic pain market is competitive and consists of a few major players. Companies like Grunenthal, Mallinckrodt Pharmaceuticals, GlaxoSmithKline Plc, J Pfizer, Inc., Cipla, Inc., Glenmark, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, among others, hold a substantial market share in the market.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Diabetic Neuropathy and Other Targetted Diseases
4.2.2 Increasing Healthcare Expenditure and Research Funding
4.3 Market Restraints
4.3.1 Side Effects of Treatments and Availability of Counterfeit Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Indication
5.1.1 Diabetic Neuropathy
5.1.2 Spinal Stenosis
5.1.3 Chemotherapy-induced Peripheral Neuropathy
5.1.4 Others
5.2 By Drug Class
5.2.1 Tricyclic Antidepressants
5.2.2 Opioids
5.2.3 Capsaicin Cream
5.2.4 Steroids
5.2.5 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Grunenthal
6.1.2 Mallinckrodt Pharmaceuticals
6.1.3 GlaxoSmithKline Plc
6.1.4 Pfizer, Inc.
6.1.5 Cipla, Inc. (InvaGen Pharma)
6.1.6 Glenmark
6.1.7 Centaur Pharmaceuticals
6.1.8 Sun Pharmaceutical Industries Ltd.
6.1.9 Teva Pharmaceutical Industries Ltd.
6.1.10 Dr. Reddy's Laboratories Ltd.
6.1.11 Lupin Ltd.
6.1.12 Laurus Labs
6.1.13 Lannett Co Inc
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security